PIISVYWK
PIISVYWK is an orally active PPARγ Inhibitor, heme oxygenase-1 Activator, and Nrf2 Activator. PIISVYWK mediates activity via the HO-1/Nrf2 pathway, ameliorates oxidative stress, reduces inflammation, and mediates anti-obesity activity. PIISVYWK can be used for the research of obesity.
For research use only. We do not sell to patients.
- CAS No.: 2016043-80-2
- Formula: C51H76N10O11
- Molecular Weight:1005.21
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
PIISVYWK (10-100 μM; 48 h) is non-cytotoxic to BMMSCs[1].
PIISVYWK (10-100 μM; 7 days) inhibits adipocyte differentiation in BMMSCs by suppressing adipogenic transcription factors and lipogenic enzymes, and enhancing lipolysis, with up to 40.97% inhibition of lipid accumulation at 100 μM[1].
PIISVYWK (10-100 μM; 2 days for Nrf2, 3 days for HO-1) activates the HO-1/Nrf2 signaling pathway in BMMSCs, increasing HO-1 cytoplasmic expression and Nrf2 nuclear expression at 100 μM[1].
PIISVYWK (10-100 μM; 7 days) reduces oxidative stress in BMMSCs during adipogenesis by decreasing ROS generation and increasing antioxidant enzyme activities, with significant effects at 100 μM[1].
PIISVYWK (10-100 μM; 7 days) reduces inflammation in BMMSCs by suppressing pro-inflammatory cytokine production and modulating the MAPK pathway, with significant effects at 100 μM[1].
PIISVYWK (100 μM; 7 days, pre-treated with 5 μM ZnPP for 1 h) exerts anti-adipogenic effects in BMMSCs that are mediated by HO-1, as pre-treatment with ZnPP reverses its inhibitory effects on adipocyte differentiation, transcription factor expression, and lipolysis[1].
PIISVYWK (100 μM; 7 days, pre-treated with 5 μM ZnPP for 1 h) exerts oxidative stress-reducing and anti-inflammatory effects in BMMSCs that are mediated by HO-1, as pre-treatment with ZnPP reverses these effects[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:bone marrow-derived mesenchymal stem cells (BMMSCs)
-
Concentration:10-100 μM
-
Incubation Time:7 days
-
Result:Inhibited lipid accumulation in BMMSCs in a dose-dependent manner, with up to 40.97% inhibition at 100 μM; suppressed the expression of adipogenic transcription factors PPARγ, SREBP-1, and C/EBPα, alongside adipocyte protein 2 (aP2); increased free glycerol levels in the culture medium; inhibited lipogenic enzymes FAS and LPL; upregulated lipolysis-related p-HSL.
-
Cell Line:bone marrow-derived mesenchymal stem cells (BMMSCs)
-
Concentration:10-100 μM
-
Incubation Time:2 days (Nrf2); 3 days (HO-1)
-
Result:Elevated HO-1 expression in the cytoplasm of BMMSCs, with significance at 100 μM (P < 0.05); increased Nrf2 expression in the cell nucleus at high concentrations (P < 0.05); induced Nrf2 nuclear translocation as observed via immunostaining.
-
Cell Line:bone marrow-derived mesenchymal stem cells (BMMSCs)
-
Concentration:10-100 μM
-
Incubation Time:7 days
-
Result:Significantly reduced the production of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in BMMSCs compared to the control group, with significant effects at higher concentrations (P < 0.01 for 100 μM; P < 0.05 for lower concentrations); modulated the MAPK pathway, with changes in p-ERK, p-P38, and p-JNK expression.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 3 weeks old at acclimation start, 6 weeks old at study initiation, HFD-induced obesity model)[1]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 15 weeks
-
Result:Reduced weight gain to 17.29 g, decreased fat percentage to 45.26%, reduced adipose tissue weight, suppressed adipogenic transcription factors (PPARγ, SREBP-1, C/EBPα) and lipogenic enzymes (LPL, FAS, aP2) in subcutaneous adipose tissue, increased p-HSL and p-AMPK expression in subcutaneous adipose tissue, reduced fasting blood glucose to 146.00 mg/dL, reduced total cholesterol (4.98 mmol/L), LDL (1.00 mmol/L), and triglycerides (1.43 mmol/L), increased HDL (1.49 mmol/L) and free glycerol levels, reduced serum pro-inflammatory cytokines (IL-6: 34.33 pg/mL, IL-1β: 17.00 pg/mL, TNFα: 22.67 pg/mL), increased antioxidant enzyme activities (CAT: 35.4 U/mL, SOD: 165.2 U/mL, GPx: 82.7 U/mL), and activated HO-1 and Nrf2 in subcutaneous adipose tissue at 10 mg/kg; moderately reduced weight gain, fasting blood glucose, LDL, pro-inflammatory cytokines, and increased antioxidant enzyme activities at 1 mg/kg.
Chemical Information
-
CAS No. 2016043-80-2
-
Molecular Weight 1005.21
-
Formula C51H76N10O11
-
Sequence
Pro-Ile-Ile-Ser-Val-Tyr-Trp-Lys
-
Sequence Shortening
PIISVYWK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PIISVYWK
- 2016043-80-2
- PPAR
- Reactive Oxygen Species (ROS)
- Keap1-Nrf2
- nuclear factor erythroid 2-related factor 2
- CCAAT/enhancer-binding protein alpha
- heme oxygenase-1
- bone marrow-derived mesenchymal stem cell
- AMP-activated protein kinase
- peroxisome proliferator-activated receptor gamma
- mitogen-activated protein kinase pathway
- hormone-sensitive lipase
- sterol regulatory element-binding protein 1
- high-fat diet-induced obese mice
- Inhibitor
- inhibitor
- inhibit